As high drug prices continue to incite public outcry and US legislation, it is nonetheless possible that Regeneron Pharmaceuticals’ drug for a rare cholesterol condition could lock in as much as $500,000 annually, according to reporting from Reynald Castaneda and Bernarda Tundzhay, Pharma Writers for the Investigative News team at GlobalData, a leading data and analytics company.

That said, with resistance expected from insurers, a lower price for evinacumab for homozygous familial hypercholesterolemia (HoFH) is still a possibility.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Castaneda and Tundzhay commented: “Pushback, particularly from patients, due to an anticipated high coinsurance is also likely considering evinacumab may be used on top of other therapies they need to take.”

Inevitably, there will be patient assistance programs and evinacumab could be priced between the cost of Amgen’s Repatha and half that of Amryt Pharma’s Juxtapid, both approved in HoFH. Regeneron plans to submit an application to the US Food and Drug Administration in mid-2020.

Castaneda and Tundzhay noted: “In term of competition, evinacumab may be preferred over Repatha but the latter also has cholesterol reduction benefit and more robust safety data that keeps it firmly in the treatment paradigm.”

In terms of competitors developing therapies for HoFH, Novartis and LIB Therapeutics have Phase III trials; LipimetiX Development, AD Pharmaceuticals and RegenxBio have Phase II studies; and Innovent Biologics and Madrigal Pharmaceuticals have Phase I trials, according to GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.